```html

Zollinger‑Ellison Disease (ZED) – A Patient‑Friendly Medical Guide

Overview

Zollinger‑Ellison disease (ZED) is a rare, chronic condition characterized by one or more gastrin‑producing tumors (gastrinomas) that arise in the pancreas or duodenum. These tumors secrete excessive amounts of the hormone gastrin, which in turn stimulates the stomach to produce large volumes of gastric acid. The resulting hyperacidity can lead to severe peptic ulcers, diarrhea, and malabsorption.

Who it affects: ZED can occur at any age but most commonly appears in adults aged 30‑60 years. Both sexes are affected equally, although some series suggest a mild male predominance (≈55%).

Prevalence: Gastrinomas are the second most common functional neuroendocrine tumor of the pancreas, with an estimated incidence of 0.5–2 cases per million people per year and a prevalence of roughly 2–5 per 100,000 [1][2]. Approximately 20‑25% of gastrinomas are part of the inherited multiple endocrine neoplasia type 1 (MEN‑1) syndrome.

Symptoms

The hallmark of ZED is acid‑related gastrointestinal distress, but the clinical picture can be variable. Symptoms often develop gradually, leading to delayed diagnosis.

Gastro‑intestinal symptoms

• Refractory peptic ulcers: Ulcers that fail to heal despite standard therapy, often located beyond the duodenum (jejunal, ileal).
• Abdominal pain: Burning or gnawing pain that may worsen after meals.
• Diarrhea: Occurs in up to 75 % of patients; stools are often watery, sometimes greasy, due to malabsorption of fats and fat‑soluble vitamins.
• Gastro‑esophageal reflux disease (GERD): Excess acid aggravates reflux symptoms.
• Nausea & vomiting: May be triggered by the high acid load.

Systemic symptoms

• Weight loss: Resulting from chronic diarrhea, malabsorption, and decreased appetite.
• Fatigue & weakness: Due to anemia, electrolyte disturbances (e.g., hypokalemia), or vitamin deficiencies.
• Steatorrhea: Foul‑smelling, bulky stools when fat malabsorption is severe.
• Osteoporosis: Chronic acid exposure can impair calcium absorption.

Symptoms related to tumor location or spread

• Abdominal mass or palpable lump: Uncommon but can be felt if the tumor grows large.
• Back or flank pain: May indicate tumor invasion into surrounding structures.
• Signs of metastatic disease: Liver metastases can cause right‑upper‑quadrant discomfort, jaundice, or ascites.

Causes and Risk Factors

Zollinger‑Ellison disease is caused by the development of gastrin‑producing neuroendocrine tumors (NETs). The exact trigger for sporadic gastrinomas remains unknown, but several risk factors are recognized.

Genetic factors

• Multiple endocrine neoplasia type 1 (MEN‑1): An autosomal‑dominant mutation in the MEN1 gene; accounts for ~20‑25 % of ZED cases.
• Familial gastrinoma syndrome: A rarer inherited form distinct from MEN‑1, linked to mutations on chromosome 11q13.

Environmental & lifestyle factors

• There is no clear link to smoking, alcohol, or diet, unlike many other peptic‑ulcer disorders.
• Chronic use of proton‑pump inhibitors (PPIs) does not cause gastrinomas, but long‑term PPI therapy can mask early symptoms, potentially delaying diagnosis.

Other risk considerations

• Age: Incidence rises after the third decade.
• Sex: Slight male predominance.
• Previous gastric surgery: Not a cause, but altered anatomy can complicate symptom interpretation.

Diagnosis

Because symptoms overlap with common ulcer disease, a high index of suspicion is essential. Diagnosis combines biochemical testing, imaging, and sometimes endoscopic evaluation.

Biochemical tests

• Fasting serum gastrin level: Values > 1,000 pg/mL are highly suggestive; however, levels > 150 pg/mL with a gastric pH < 2 are diagnostic when other causes of hypergastrinemia (e.g., PPI use, atrophic gastritis) are excluded.
• Secretin stimulation test: A rise in gastrin ≥ 120 pg/mL after IV secretin infusion supports ZED, especially when fasting gastrin is only modestly elevated.
• Gastric pH measurement: Acidic pH (< 2) confirms the functional effect of gastrin excess.

Imaging studies

• Somatostatin receptor scintigraphy (SRS) / ^68Ga‑DOTATATE PET‑CT: Most sensitive for locating primary gastrinomas and detecting metastases.
• Endoscopic ultrasound (EUS): Excellent for identifying small pancreatic lesions (< 1 cm).
• Multiphasic CT or MRI abdomen: Provides anatomical detail; detects liver metastases in 30‑50 % of patients at diagnosis.

Endoscopic evaluation

• Upper endoscopy (EGD): Visualizes ulcers and may obtain biopsies to rule out Helicobacter pylori or malignancy.
• Capsule endoscopy or double‑balloon enteroscopy: Useful for detecting jejunal/ileal ulcers that are out of reach of standard endoscopy.

Pathology

If surgical resection is performed, the tumor is examined histologically. Gastrinomas are classified as well‑differentiated neuroendocrine tumors, usually Grade 1 or 2 based on Ki‑67 index.

Treatment Options

Management has two primary goals: control acid hypersecretion and eradicate or control the tumor.

Acid‑suppression therapy (first line)

• Proton‑pump inhibitors (PPIs): High‑dose omeprazole 40–80 mg daily (or equivalent) is the mainstay; most patients achieve symptom control within days.
• H2‑receptor antagonists: Can be added if residual acid output persists, but PPIs are far more effective.
• Long‑term PPI use is generally safe; routine monitoring of vitamin B12, magnesium, and calcium is recommended because chronic hypochlorhydria can affect absorption.

Surgical management

• Curative resection: Preferred for solitary, well‑localized gastrinomas without metastasis. Enucleation or pancreaticoduodenectomy may be required depending on location.
• Debulking surgery: In metastatic disease, removal of > 90 % of tumor bulk can improve symptom control and prolong survival.
• Peri‑operative octreotide infusion can reduce intra‑operative acid output.

Medical therapies for tumor control

• Somatostatin analogues (e.g., octreotide, lanreotide): Bind to somatostatin receptors, inhibiting gastrin release and tumor growth. Standard dose: octreotide 30–50 mg IM every 28 days.
• Targeted therapy (everolimus): mTOR inhibitor approved for progressive neuroendocrine tumors; may shrink gastrinomas.
• Chemotherapy: Generally reserved for high‑grade or rapidly progressing disease; regimens include streptozocin‑based combos.

Interventional radiology & ablative techniques

• Trans‑arterial embolization (TAE): Used for liver metastases to control tumor burden.
• Radiofrequency ablation (RFA) or microwave ablation: Local control of hepatic lesions.

Lifestyle and supportive measures

• Dietary modifications: Small, low‑fat meals; avoid irritants (caffeine, alcohol, spicy foods) that can exacerbate acid output.
• Nutrient supplementation: Monitor and replace vitamins B12, D, calcium, and magnesium as needed.
• Bone health: DEXA scanning every 2–3 years; consider bisphosphonates if osteoporosis develops.

Living with Zollinger‑Ellison Disease

While ZED is chronic, many patients lead full, active lives with appropriate treatment and monitoring.

Daily management tips

• Take PPIs exactly as prescribed; never skip doses.
• Keep a symptom diary (pain, stool frequency, weight) to discuss with your gastroenterologist.
• Schedule regular follow‑up labs: fasting gastrin, vitamin B12, magnesium, calcium, and liver function tests.
• Engage in moderate exercise to support bone density and overall well‑being.
• Join patient support groups (e.g., NETPatient.org) for education and emotional support.

Monitoring schedule

• Every 6–12 months: Endoscopy to assess ulcer healing.
• Annually: Imaging (CT/MRI or ^68Ga‑DOTATATE PET) to detect new lesions.
• Every 1–2 years: Hormone panel (gastrin) and nutritional labs.

Prevention

Because most gastrinomas are sporadic, primary prevention is limited. However, certain actions can reduce complications and aid early detection:

• Screen high‑risk families: First‑degree relatives of patients with MEN‑1 or familial gastrinoma should undergo genetic counseling and periodic gastrin testing.
• Avoid long‑term unnecessary PPI use: Unwarranted acid suppression may mask early symptoms and lead to delayed diagnosis.
• Prompt evaluation of refractory ulcers or unexplained diarrhea: Early referral to a gastroenterologist can catch ZED before metastasis.

Complications

If untreated or inadequately controlled, ZED can lead to serious health problems.

• Peptic ulcer disease complications: Perforation, bleeding, obstruction, or fistula formation.
• Gastro‑intestinal bleeding: May require endoscopic hemostasis or transfusion.
• Malnutrition and electrolyte disturbances: Chronic diarrhea can cause severe hypokalemia, metabolic alkalosis, and vitamin deficiencies.
• Liver metastasis: Occurs in up to 50 % of patients; associated with reduced survival (median 5‑year survival 60 % for localized disease vs. 30 % for metastatic).
• Rare neuroendocrine tumor dedifferentiation: High‑grade transformation carries a poorer prognosis.
• Bone disease: Osteopenia/osteoporosis from chronic acid exposure and malabsorption.

When to Seek Emergency Care

References

1. Mayo Clinic. “Zollinger‑Ellison syndrome.” Updated 2023. https://www.mayoclinic.org
2. American Cancer Society. “Neuroendocrine Tumors of the Pancreas.” 2022. https://www.cancer.org
3. National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). “Zollinger‑Ellison Syndrome.” 2021. https://www.niddk.nih.gov
4. European Neuroendocrine Tumor Society (ENETS) Guidelines. “Management of Gastrinomas.” 2020. https://www.enets.org
5. Cleveland Clinic. “Gastrinomas and Zollinger‑Ellison Syndrome.” 2023. https://my.clevelandclinic.org
6. World Health Organization. “Neuroendocrine Tumors.” WHO Classification of Tumours, Digestive System, 5th Edition, 2022.

```